Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 352.4, up 0.14% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74685.25, up 0.72%. Biocon Ltd has dropped around 4.94% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 10.32 lakh shares today, compared to the daily average of 28.66 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 353.5, up 0.14% on the day. Biocon Ltd is down 5.29% in last one year as compared to a 10.18% fall in NIFTY and a 22.72% fall in the Nifty Pharma index.
The PE of the stock is 190.27 based on TTM earnings ending June 26.
Biocon announced that it has been ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceutical, pharmaceutical, and related industries in the 2026 survey conducted by the prestigious U.S.-based Science magazine.
This recognition reflects Biocon's long-standing reputation as an employer of choice in the global life sciences industry. Since making its debut on the highly regarded Science Careers Top Employers list in 2012, Biocon has consistently featured among the industry's leading employers.
In the 2026 survey, Biocon was recognized for three key attributes: social responsibility, respect for employees, and a culture aligned with employee values.
Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 345.5, up 3.93% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73291.61, down 0.42%. Biocon Ltd has slipped around 8.36% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 23.24 lakh shares today, compared to the daily average of 27.22 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 348.85, up 4.1% on the day. Biocon Ltd is down 7.55% in last one year as compared to a 12.85% drop in NIFTY and a 18.23% drop in the Nifty Pharma index.
The PE of the stock is 180.43 based on TTM earnings ending June 26.
Biocon has signed a license agreement with Janssen Sciences Ireland clearing the way for the commercialization of Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect.
This milestone builds on the Company's previously announced agreements with Janssen that secured market entry dates for Yesintek™ in the United States, and in Europe, the UK, Canada and Japan.
These additional market entry rights for biosimilar Ustekinumab will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets.
Yesintek™ is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signalling in immune mediated diseases and has been approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara®, had worldwide sales of $6.08 billion in 2025.
Biocon Ltd dropped for a fifth straight session today. The stock is quoting at Rs 319.15, down 3.38% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.24% on the day, quoting at 22406.15. The Sensex is at 72534.84, down 0.98%.Biocon Ltd has lost around 17.53% in last one month.Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has eased around 7.21% in last one month and is currently quoting at 25596.65, down 2.02% on the day. The volume in the stock stood at 22.29 lakh shares today, compared to the daily average of 25.68 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 319.05, down 3.51% on the day. Biocon Ltd tumbled 11.22% in last one year as compared to a 13.14% slide in NIFTY and a 12.18% spurt in the Nifty Pharma index.
The PE of the stock is 178.24 based on TTM earnings ending June 26.
Biocon has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch dates for Pebrilzo®, its biosimilar to the reference product Perjeta® (Pertuzumab).
Biocon and Genentech executed the patent settlement agreement to resolve all pending disputes between the companies, including in the U.S., Canada, and other jurisdictions.
This global patent settlement and license agreement enables Biocon to launch Pebrilzo® in Q1 of calendar year (CY) 2027 in the European Union and UK, Q3 of CY 2028 in the U.S., and in CY 2026-2028 in other Rest of the World (RoW) countries or earlier in certain circumstances.
The other terms of the agreement are confidential.
Pebrilzo® is a biosimilar medicinal product and the active substance is Pertuzumab, a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2. Pebrilzo® is used for the treatment of HER2-positive breast cancer across multiple disease stages.
Biocon Ltd dropped for a fifth straight session today. The stock is quoting at Rs 346.3, down 1.06% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.19% on the day, quoting at 22497.45. The Sensex is at 72413.6, up 1.15%.Biocon Ltd has lost around 11.58% in last one month.Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has eased around 2.39% in last one month and is currently quoting at 25823.25, up 0.38% on the day. The volume in the stock stood at 9.66 lakh shares today, compared to the daily average of 31.2 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 348.55, down 0.19% on the day. Biocon Ltd tumbled 2.02% in last one year as compared to a 11.03% slide in NIFTY and a 16.66% spurt in the Nifty Pharma index.
The PE of the stock is 188.65 based on TTM earnings ending June 26.
In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.
The announcement was made before market hours today, 25 September 2026.
Biocon is a Bengaluru-based biopharmaceutical company focused on biosimilars and generic medicines, with operations across more than 120 countries.
The company had reported 355% jump in consolidated net profit to Rs 141 crore in Q1 FY27 from Rs 31 crore in Q1 FY26. Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.
The scrip shed 0.58% to currently trade at Rs 384.75 on the BSE.
The positive opinion follows the review of a marketing authorisation application submitted by Biocon Biologics Ireland, an indirect wholly owned subsidiary of Biocon Biologics.
Biocon said its Pertuzumab biosimilar is the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA's tailored clinical development approach. The company said the application was supported by structural and functional analytical characterisation and comparative clinical pharmacokinetic data.
The European Commission will now conduct the final review and decide on marketing authorisation. Biocon said Pebrilzo is not authorised for use in the European Union until marketing authorisation is granted.
Pebrilzo contains Pertuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is indicated for use with Trastuzumab and chemotherapy in certain patients with HER2-positive early-stage or locally advanced breast cancer. It is also indicated with Trastuzumab and Docetaxel for certain patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.
Biocon said comparative analytical and clinical pharmacokinetic data demonstrated high similarity between Pebrilzo and the reference biologic, with no clinically meaningful differences in quality, safety or efficacy.